- Home
- SMID vs AARD Comparison
SMID vs AARD Comparison
Compare SMID & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMID
- AARD
- Stock Information
- Founded
- SMID 1960
- AARD 2017
- Country
- SMID United States
- AARD United States
- Employees
- SMID N/A
- AARD N/A
- Industry
- SMID Building Materials
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- SMID Industrials
- AARD Health Care
- Exchange
- SMID Nasdaq
- AARD Nasdaq
- Market Cap
- SMID 157.4M
- AARD 154.9M
- IPO Year
- SMID 1995
- AARD 2025
- Fundamental
- Price
- SMID $37.91
- AARD $12.20
- Analyst Decision
- SMID
- AARD Strong Buy
- Analyst Count
- SMID 0
- AARD 5
- Target Price
- SMID N/A
- AARD $33.00
- AVG Volume (30 Days)
- SMID 21.7K
- AARD 85.2K
- Earning Date
- SMID 07-10-2025
- AARD 08-14-2025
- Dividend Yield
- SMID N/A
- AARD N/A
- EPS Growth
- SMID 444.88
- AARD N/A
- EPS
- SMID 1.86
- AARD N/A
- Revenue
- SMID $84,450,000.00
- AARD N/A
- Revenue This Year
- SMID N/A
- AARD N/A
- Revenue Next Year
- SMID N/A
- AARD N/A
- P/E Ratio
- SMID $20.57
- AARD N/A
- Revenue Growth
- SMID 33.01
- AARD N/A
- 52 Week Low
- SMID $25.13
- AARD $4.88
- 52 Week High
- SMID $51.96
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- SMID 71.21
- AARD N/A
- Support Level
- SMID $32.85
- AARD N/A
- Resistance Level
- SMID $35.37
- AARD N/A
- Average True Range (ATR)
- SMID 1.63
- AARD 0.00
- MACD
- SMID 0.51
- AARD 0.00
- Stochastic Oscillator
- SMID 82.07
- AARD 0.00
About SMID Smith-Midland Corporation
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.